Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
The median survival of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) has more than doubled, since the discovery of HER2-targeted treatments: it rose from less than 2 years in 2001 (prior introduction of trastuzumab) to more than 4 years in 2017...
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2018-04-01
|
| Collection: | Frontiers in Oncology |
| Sujets: | |
| Accès en ligne: | http://journal.frontiersin.org/article/10.3389/fonc.2018.00089/full |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|